Vident Investment Advisory, LLC Autolus Therapeutics PLC Transaction History

Vident Investment Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 17, 2020	SELL	$5.38 - $16.14 $601,656 - $1.8 Million	-111,832 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$4.2 - $13.0 $29,542 - $91,442	-7,034 Reduced 5.92%	111,832 $670,000
Q4 2019 Feb 11, 2020	BUY	$11.13 - $16.28 $344,506 - $503,914	30,953 Added 35.21%	118,866 $1.57 Million
Q3 2019 Nov 13, 2019	SELL	$9.79 - $16.72 $24,592 - $42,000	-2,512 Reduced 2.78%	87,913 $1.09 Million
Q2 2019 Aug 12, 2019	BUY	$15.1 - $31.25 $1.37 Million - $2.83 Million	90,425 New	90,425 $1.46 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.